These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 20599702)
1. Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15. Puddu A; Storace D; Durante A; Odetti P; Viviani GL Biochem Biophys Res Commun; 2010 Jul; 398(3):462-6. PubMed ID: 20599702 [TBL] [Abstract][Full Text] [Related]
2. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Puddu A; Sanguineti R; Durante A; Viviani GL Regul Pept; 2012 Aug; 177(1-3):79-84. PubMed ID: 22587907 [TBL] [Abstract][Full Text] [Related]
3. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Granata R; Settanni F; Gallo D; Trovato L; Biancone L; Cantaluppi V; Nano R; Annunziata M; Campiglia P; Arnoletti E; Ghè C; Volante M; Papotti M; Muccioli G; Ghigo E Diabetes; 2008 Apr; 57(4):967-79. PubMed ID: 18162507 [TBL] [Abstract][Full Text] [Related]
4. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1. Green BD; Liu HK; McCluskey JT; Duffy NA; O'Harte FP; McClenaghan NH; Flatt PR Diabetes Obes Metab; 2005 Sep; 7(5):563-9. PubMed ID: 16050949 [TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Ishibashi Y; Nishino Y; Matsui T; Takeuchi M; Yamagishi S Metabolism; 2011 Sep; 60(9):1271-7. PubMed ID: 21388644 [TBL] [Abstract][Full Text] [Related]
6. [Effects of glucagon-like peptide-1 on the free fatty acid-induced expression of pancreatic derived factor in cultured β-TC3 cell line]. Chen S; Cao XP; Xiao HP; Li YB Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1413-6. PubMed ID: 21756815 [TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis of Beta cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus. Lim M; Park L; Shin G; Hong H; Kang I; Park Y Ann N Y Acad Sci; 2008 Dec; 1150():311-5. PubMed ID: 19120318 [TBL] [Abstract][Full Text] [Related]
8. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Fan R; Li X; Gu X; Chan JC; Xu G Diabetes Obes Metab; 2010 Sep; 12(9):815-24. PubMed ID: 20649634 [TBL] [Abstract][Full Text] [Related]
10. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Green BD; Gault VA; O'Harte FP; Flatt PR Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953 [TBL] [Abstract][Full Text] [Related]
11. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice. Pacini G; Thomaseth K; Ahrén B Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002 [TBL] [Abstract][Full Text] [Related]
12. The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products. Mruthinti S; Sood A; Humphrey CL; Swamy-Mruthinti S; Buccafusco JJ Neuroscience; 2006 Oct; 142(2):463-73. PubMed ID: 16890367 [TBL] [Abstract][Full Text] [Related]
13. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370 [TBL] [Abstract][Full Text] [Related]
14. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. Asmar M; Højberg PV; Deacon CF; Hare K; Holst JJ; Madsbad S Regul Pept; 2010 Feb; 160(1-3):175-80. PubMed ID: 20005261 [TBL] [Abstract][Full Text] [Related]
15. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Gallwitz B Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937 [TBL] [Abstract][Full Text] [Related]
16. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Klinger S; Poussin C; Debril MB; Dolci W; Halban PA; Thorens B Diabetes; 2008 Mar; 57(3):584-93. PubMed ID: 18025410 [TBL] [Abstract][Full Text] [Related]